Need for improvements in reported cost effectiveness of adalimumab in rheumatoid arthritis

Z Rheumatol. 2017 Mar;76(2):183-184. doi: 10.1007/s00393-016-0255-3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adalimumab*
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Cost-Benefit Analysis*
  • Etanercept
  • Humans
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Adalimumab
  • Etanercept